Viral Hepatitis

You have full text access to this OnlineOpen article

Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials†

  1. Naga Chalasani1,‡,*,
  2. Cosme Manzarbeitia2,
  3. Peter Ferenci3,
  4. Wolfgang Vogel4,
  5. Robert J. Fontana5,
  6. Michael Voigt6,
  7. Caroline Riely7,
  8. Paul Martin8,
  9. Lewis Teperman9,
  10. James Jiao10,
  11. Juan Carlos Lopez-Talavera10

Article first published online: 19 JAN 2005

DOI: 10.1002/hep.20560

Issue

Hepatology

Hepatology

Volume 41, Issue 2, pages 289–298, February 2005

Additional Information

How to Cite

Chalasani, N., Manzarbeitia, C., Ferenci, P., Vogel, W., Fontana, R. J., Voigt, M., Riely, C., Martin, P., Teperman, L., Jiao, J. and Lopez-Talavera, J. C. (2005), Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology, 41: 289–298. doi: 10.1002/hep.20560

Author Information

  1. 1

    Indiana University Medical Center, Indianapolis IN

  2. 2

    Albert Einstein Medical Center, Philadelphia, PA

  3. 3

    University of Vienna, Austria

  4. 4

    University of Innsbruck, Austria

  5. 5

    University of Michigan Medical Center, Ann Arbor, MI

  6. 6

    University of Iowa Hospital, Iowa City, IA

  7. 7

    University of Tennessee, Memphis, TN

  8. 8

    Cedar-Sinai Medical Center, Los Angeles, CA

  9. 9

    NYU Medical Center, New York, NY

  10. 10

    Roche Laboratories Inc., Nutley, NJ

  1. ‡

    fax: 317-630-6815

*Indiana University School of Medicine, WD OPW 2005, 1001 West 10th Street, Indianapolis, IN 46202

  1. †

    Conflict of interest: Nothing to report.

  2. ‡

    fax: 317-630-6815

Publication History

  1. Issue published online: 19 JAN 2005
  2. Article first published online: 19 JAN 2005
  3. Manuscript Accepted: 21 NOV 2004
  4. Manuscript Received: 4 AUG 2004

Funded by

  • Roche Laboratories Inc., Nutley, NJ

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (201K)

References

  • 1
    Costa MA, Schiff ER. Hepatitis C. Curr Treat Options Gastroenterol 1999; 2: 481-490.
  • 2
    Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
  • 3
    Willems M, Metselaar HJ, Tilanus HW, Schalm SW, de Man RA. Liver transplantation and hepatitis C. Transpl Int 2002; 15: 61-72.
    Direct Link:
  • 4
    Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-678.
  • 5
    Sheiner P, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. HEPATOLOGY 1998; 28: 831-838.
    Direct Link:
  • 6
    Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 82-86.
  • 7
    Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997; 29: 519-521.
  • 8
    Mazaaferro V, Tagger A, Schiavo M, Regalia E. Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin. Transplant Proc 2001; 33: 13555-13579.
  • 9
    Terrault NA, Khalili M, Straley S, Bollinger K, Bass N, Roberts JP, et al. Efficacy and tolerability of preemptive interferon versus interferon plus ribavirin (RBV) treatment in hepatitis C virus (HCV) infected liver transplant recipients [Abstract]. HEPATOLOGY 2003; 38: 158.
  • 10
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650.
  • 11
    Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant Proc 2003; 35: 1478-1479.
  • 12
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-173.
    Direct Link:
  • 13
    Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-194.
  • 14
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674.
  • 15
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 16
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  • 17
    Banff schema for grading liver allograft rejection: an international consensus document. HEPATOLOGY 1997; 25: 658-663.
    Direct Link:
  • 18
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
  • 19
    Bahr MJ, Manns MP. Changing faces: natural course and treatment of hepatitis C after liver transplantation. J Hepatol 2004; 40: 699-701.
  • 20
    Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850-858.
    Direct Link:
  • 21
    Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-867.
    Direct Link:
  • 22
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000-1006.
    Direct Link:
  • 23
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199-207.
    Direct Link:
  • 24
    Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. HEPATOLOGY 1997; 26: 500-504.
    Direct Link:
  • 25
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomized study of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7: 863-869.
    Direct Link:
  • 26
    Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7: 870-876.
    Direct Link:
  • 27
    Jain AB, Eghtesad B, Venkataramanan R, Fontes PA, Kashyap R, Dvorchik I, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8: 1007-1013.
    Direct Link:
View Full Article (HTML) Get PDF (201K)